CLDI
Calidi Biotherapeutics, Inc.
$0.1750
+3.55%
$3.4M
No data for this timeframe.
Vol
Market Cap$3.4M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$68.2K
Inst. Activity3 buys / 0 sells
Press Releases6
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001855485·Prev Close $0.1690
Recent Activity
Inst.
FMR LLC — DOUBLED
22,013 shares ($25.8K)
Inst.
MORGAN STANLEY — DOUBLED
1,467 shares ($1.7K)
Jun 9, 2026
short_volume
Short Volume: CLDI — 64.7% short (1.2M / 1.9M)
Short: 1,217,651 | Exempt: 0 | TRF Vol: 1,881,951 | Short Ratio: 64.7% | Off-exchange volume (dark p
May 26, 2026
Press
Calidi Biotherapeutics announced that two abstracts on its RedTail platform (CLD-401 and CLD-501) were accepted for publ
Impact 4/10
May 22, 2026
Press
Calidi Biotherapeutics disclosed an audit report with a going-concern emphasis in its 2025 Form 10-K, required by NYSE A
Impact 7/10
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 27, 2024 | Ladenburg Thalmann | INITIATE | Buy |
| May 15, 2024 | Baird | MAINTAIN | Outperform → Outperform |
| Mar 21, 2024 | Baird | MAINTAIN | Outperform → Outperform |
| Mar 21, 2024 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Nov 22, 2023 | HC Wainwright & Co. | INITIATE | Buy |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $40.6K | NEW |
| FMR LLC | $25.8K | DOUBLED |
| MORGAN STANLEY | $1.7K | DOUBLED |
| BANK OF AMERICA CORP | $53.00 | ADD |
4 institutional holders with $68.2K total value (58,254 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 34,728 | $40.6K | 59.6% | NEW |
| 2 | FMR LLC | 22,013 | $25.8K | 37.8% | DOUBLED +17510.4% |
| 3 | MORGAN STANLEY | 1,467 | $1.7K | 2.5% | DOUBLED +279.1% |
| 4 | BANK OF AMERICA CORP /DE/ | 46 | $53.00 | 0.1% | ADD +53.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 125 | 22,013 | +17510.4% | $25.8K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 387 | 1,467 | +279.1% | $1.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 30 | 46 | +53.3% | $53.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 34,728 | — | $52.8K | 2025-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
NEUTRAL
4/10
Calidi Biotherapeutics announced that two abstracts on its RedTail platform (CLD-401 and CLD-501) we
May 26, 2026
BEARISH
7/10
Calidi Biotherapeutics disclosed an audit report with a going-concern emphasis in its 2025 Form 10-K
May 22, 2026
BULLISH
7/10
Calidi Biotherapeutics presented preclinical data at AACR demonstrating its RedTail platform's abili
Apr 20, 2026
MIXED
5/10
Calidi Biotherapeutics reported Q4 and full-year 2025 financial results, showing a narrowed net loss
Mar 27, 2026
BEARISH
7/10
Calidi Biotherapeutics (CLDI) has closed a public offering, raising approximately $6.0 million in gr
Mar 10, 2026
NEUTRAL
4/10
Calidi Biotherapeutics (CLDI) announced a proposed underwritten public offering of units consisting
Mar 5, 2026
Historical analyst distribution (last covering-analyst action Jun 2024): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 27, 2024 | Ladenburg Thalmann | INITIATE | — | Buy |
| May 15, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 21, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 21, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 22, 2023 | HC Wainwright & Co. | INITIATE | — | Buy |
| Oct 9, 2023 | Baird | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: CLDI — 64.7% short (1.2M / 1.9M)
Short: 1,217,651 | Exempt: 0 | TRF Vol: 1,881,951 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: CLDI — 59.4% short (0.6M / 1.0M)
Short: 604,631 | Exempt: 0 | TRF Vol: 1,018,204 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: CLDI — 66.9% short (0.6M / 0.8M)
Short: 551,241 | Exempt: 1,000 | TRF Vol: 823,554 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: CLDI — 61.6% short (1.0M / 1.6M)
Short: 967,211 | Exempt: 1,007 | TRF Vol: 1,568,918 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: CLDI — 59.5% short (0.5M / 0.9M)
Short: 532,742 | Exempt: 691 | TRF Vol: 895,906 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: CLDI — 60.1% short (1.5M / 2.4M)
Short: 1,468,299 | Exempt: 29,000 | TRF Vol: 2,441,329 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
<p>SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology compa
May 22, 2026
critical
Calidi Biotherapeutics Provides Required NYSE American Disclosure
<p>SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology compa
May 14, 2026
earnings
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
<p>SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology compan
May 12, 2026
short_volume
Short Volume: CLDI — 56.5% short (1.0M / 1.9M)
Short: 1,047,199 | Exempt: 793 | TRF Vol: 1,853,394 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: CLDI — 63.0% short (0.4M / 0.6M)
Short: 406,579 | Exempt: 0 | TRF Vol: 645,863 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: CLDI — 71.1% short (0.5M / 0.7M)
Short: 497,482 | Exempt: 0 | TRF Vol: 699,344 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: CLDI — 55.6% short (0.4M / 0.8M)
Short: 422,571 | Exempt: 0 | TRF Vol: 759,898 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: CLDI — 57.7% short (1.1M / 1.9M)
Short: 1,102,928 | Exempt: 222,208 | TRF Vol: 1,909,903 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_interest
FTD: CLDI — 2,518,802 shares ($0.6M) failed to deliver
Settlement: 20260429, Price: $0.22, FTD Value: $554,136.44, CALIDI BIOTHERAPEUTICS INC CL